| HYPE3 Stock | | | BRL 20.05 0.45 2.20% |
COO
Ms. Vivian Karina Trujillo Angiolucci serves as Chief Operating Officer of Hypermarcas S.A. since June 24, 2016. She joined Hypermarcas in April 2013 as Director of Strategic Projects, and also led the Generics Business Unit and Company Pharma division until assuming her current position in the company. Previously, she was associate partner at McKinsey Co. She holds a degree in Production Engineering from the Politecnico di Torino, and an MBA from Harvard Business School. since 2016.
| Age | 39 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 55 11 3627 4206 |
| Web | https://www.hyperapharma.com.br |
Hypera SA Management Efficiency
The company has return on total asset
(ROA) of
0.0686 % which means that it generated a profit of $0.0686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1626 %, meaning that it generated $0.1626 on every $100 dollars invested by stockholders. Hypera SA's management efficiency ratios could be used to measure how well Hypera SA manages its routine affairs as well as how well it operates its assets and liabilities.
Hypera SA has accumulated 6.85
B in total debt with debt to equity ratio
(D/E) of 0.7, which is about average as compared to similar companies. Hypera SA has a current ratio of 1.89, which is within standard range for the sector. Debt can assist Hypera SA until it has trouble settling it off, either with new capital or with free cash flow. So, Hypera SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hypera SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hypera to invest in growth at high rates of return. When we think about Hypera SA's use of debt, we should always consider it together with cash and equity.
It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands dermo-cosmetics products under the Mantecorp Skincare brands and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. Hypera S.A. was founded in 2001 and is headquartered in So Paulo, Brazil. HYPERA ON operates under Drug ManufacturersSpecialty Generic classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 8918 people. Hypera SA (HYPE3) is traded on Sao Paulo Exchange in Brazil and employs 9,000 people.
Management Performance
Hypera SA Leadership Team
Elected by the shareholders, the Hypera SA's board of directors comprises two types of representatives: Hypera SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hypera. The board's role is to monitor Hypera SA's management team and ensure that shareholders' interests are well served. Hypera SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hypera SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juliana Salem, Legal Officer | |
| Breno Oliveira, Investor Relations Officer, Member of the Executive Board | |
| Luciana Queiroz, Member of the Board of Directors | |
| Maria Lacerda, Independent Member of the Board of Directors | |
| David Neto, Independent Member of the Board of Directors | |
| David Coury, Independent Member of the Board of Directors | |
| Rafael Batista, Executive Officer | |
| Adalmario Couto, Chief Financial Officer, Investor Relations Officer, Business Development Officer | |
| Flair Carrilho, Independent Member of the Board of Directors | |
| Alvado Link, Member of the Board of Directors | |
| Hlio Segouras, Head Health | |
| Hugo Leal, Member of the Board of Directors | |
| Joao Aguilar, Risks Officer | |
| Mauricio Christovam, HR Officer | |
| Nelson Mello, Institutional Relations Officer, Member of the Executive Board | |
| Bernardo Hernandez, Member of the Board of Directors | |
| Vivian Angiolucci, Chief Operating Officer, Member of the Executive Board | |
| Carlos Scorsi, COO, Member of the Executive Board | |
| Luiz Clavis, Commercial and Marketing Vice President | |
| Martim Mattos, Chief Financial Officer, Chief Controllership Officer, Member of the Executive Board | |
| Esteban Fomperosa, Member of the Board of Directors | |
Hypera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hypera SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Hypera Stock Analysis
When running Hypera SA's price analysis, check to
measure Hypera SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hypera SA is operating at the current time. Most of Hypera SA's value examination focuses on studying past and present price action to
predict the probability of Hypera SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hypera SA's price. Additionally, you may evaluate how the addition of Hypera SA to your portfolios can decrease your overall portfolio volatility.